文献速递药物不良反应与药物警戒肝肾功能剂量调整

直接口服抗凝药非出血性不良事件的序列对称性分析

Non-bleeding Adverse Events with the Use of Direct Oral Anticoagulants: A Sequence Symmetry Analysis.
PubMed 文献 · Drug Saf · 2018-01-01

该研究利用法国全国医疗数据库对386,081例DOAC新使用者进行序列对称性分析,评估肾脏、肝脏、皮肤及胃肠道非出血性不良事件。结果显示DOAC与肝损伤、胃肠道药物启用及肾脏疾病存在关联信号,提示需关注罕见但严重的肝损伤及较常见的胃肠道紊乱。

要点

  • DOAC治疗与急性肝损伤信号相关(3个月时间窗aSR=2.71,95%CI 1.79-4.52)。
  • DOAC与便秘药物及止吐药启用相关(aSR=1.31和1.17)。
  • DOAC与肾脏疾病信号相关(aSR=1.33,95%CI 1.29-1.37)。

核心结论

  • 全国性研究提示DOAC与罕见但严重的肝损伤及更频繁的胃肠道紊乱相关。
  • 不能排除DOAC治疗与肾脏损伤的低风险关联。

研究设计与样本

  • 队列为386,081例DOAC新使用者,并在310,195例维生素K拮抗剂(VKA)新使用者中重复分析。

主要发现

  • DOAC或VKA治疗与住院出血及抗抑郁药启用呈预期正相关,与抗青光眼药启用无关联。
  • DOAC与肝脏结局相关,包括急性肝损伤(3个月时间窗aSR3=2.71,95%CI 1.79-4.52)。
  • DOAC与胃肠道结局相关,包括便秘药物启用(aSR3=1.31,95%CI 1.27-1.36)和止吐药启用(aSR3=1.17,95%CI 1.12-1.22)。
  • DOAC与肾脏疾病相关(aSR3=1.33,95%CI 1.29-1.37)。

关键数值与推荐

  • 肾脏、肝脏、皮肤结局通过住院出院诊断识别,胃肠道结局通过药物报销识别。
  • 调整序列比(aSR)在校正时间趋势后计算,SSA固有控制时间恒定混杂因素。
  • 使用阴性对照(青光眼)和阳性对照(出血、抑郁障碍)验证分析。

临床怎么用

  • 临床使用DOAC时应监测肝功能,警惕罕见但严重的肝损伤。
  • 关注DOAC治疗患者的胃肠道症状,如便秘或需止吐药的情况。
  • 对DOAC治疗患者应留意肾功能变化,不能排除肾脏损伤的低风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Postmarketing pharmacovigilance reports have raised concerns about non-bleeding adverse events associated with direct oral anticoagulants (DOACs), but only limited results are available from large claims databases. OBJECTIVE: The aim of this study was to assess the potential association between DOAC initiation and the onset of four types of non-bleeding adverse events by sequence symmetry analysis (SSA). METHODS: SSA was performed using nationwide data from the French National Healthcare databases (Régime Général, 50 million beneficiaries) to assess a cohort of 386,081 DOAC new users for the first occurrence of four types of non-bleeding outcomes: renal, hepatic, skin outcomes identified by using hospitalization discharge diagnoses, and gastrointestinal outcomes by using medication reimbursement. Asymmetry in the distribution of each investigated outcome occurring before and after initiation of DOAC therapy was used to test the association between DOAC therapy and these outcomes. SSA inherently controls for time-constant confounders, and adjusted sequence ratios were computed after correcting for temporal trends. Negative (glaucoma) and positive (bleeding, depressive disorders) control outcomes were used and analyses were replicated on a cohort of 310,195 patients initiating a vitamin K antagonist (VKA). RESULTS: This study demonstrated the expected positive association between either DOAC or VKA therapy and hospitalised bleeding and initiation of antidepressant therapy, while no association was observed between either DOAC or VKA therapy and initiation of antiglaucoma medications. For DOAC therapy, signals were the associations with hepatic outcomes, including acute liver injury [for the 3-month time window, aSR3 = 2.71, 95% confidence interval (CI) 1.79-4.52]; gastrointestinal outcomes, including initiation of drugs for constipation and antiemetic drugs (aSR3 = 1.31, 95% CI 1.27-1.36; and 1.17, 95% CI 1.12-1.22, respectively); and kidney diseases (aSR3 = 1.33, 95% CI 1.29-1.37). CONCLUSION: Results of this nationwide study suggest that DOACs are associated with rare but severe liver injury and more frequent gastrointestinal disorders. A low risk of kidney injury with DOAC therapy can also not be excluded.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Maura G, Billionnet C, Coste J, et al. Non-bleeding Adverse Events with the Use of Direct Oral Anticoagulants: A Sequence Symmetry Analysis. Drug Saf. 2018. PMID: 29714004. doi:10.1007/s40264-018-0668-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。